PHARMACOKINETICS OF HEPTASTIGMINE IN RATS

被引:6
作者
SEGRE, G
CERRETANI, D
BALDI, A
URSO, R
机构
[1] Institute of Pharmacology, Laboratory of Pharmacokinetics, University of Siena
关键词
HEPASTIGMINE; PHARMACOKINETICS;
D O I
10.1016/1043-6618(92)91382-Q
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Heptastigmine is a new long acting cholinesterase inhibitor that affects behaviour in a number of cognitive tests in animals. We have studied its pharmacokinetics in rats: plasma kinetics were evaluated after single intravenous dose (2 mg/kg), intramuscular (4 mg/kg) and oral (4 and 8 mg/kg) administration. Tissue distribution (heart, liver, kidney and brain) was studied after single intramuscular (4 mg/kg) and oral (8 mg/kg) administration. Plasma and tissue kinetics were also investigated after repeated oral doses (8 mg/kg b.i.d. for 7 days). Heptastigmine levels in plasma and tissues were determined using an HPLC method with an electrochemical detector. After a single dose, heptastigmine remained for a long time in plasma (the terminal half-life was about 12 h), distributed widely in tissue (the volume of distribution was about 61) and brain concentrations were very high (4-22 times those found in plasma). After repeated oral doses, the drug levels increased plasma and, to a lesser extent, in liver and kidney. © 1992.
引用
收藏
页码:139 / 146
页数:8
相关论文
共 13 条
[1]   MECHANISMS OF CHOLINESTERASE INHIBITION IN SENILE DEMENTIA OF THE ALZHEIMER TYPE - CLINICAL, PHARMACOLOGICAL, AND THERAPEUTIC ASPECTS [J].
BECKER, RE ;
GIACOBINI, E .
DRUG DEVELOPMENT RESEARCH, 1988, 12 (3-4) :163-195
[2]   PHYSIOLOGICAL MODELING OF CYCLOSPORINE KINETICS IN RAT AND MAN [J].
BERNAREGGI, A ;
ROWLAND, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (01) :21-50
[3]   DETERMINATION OF PHYSOSTIGMINE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BRODIE, RR ;
CHASSEAUD, LF ;
ROBBINS, AD .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 415 (02) :423-431
[4]   ANTICHOLINESTERASE ACTIVITY OF A NEW CARBAMATE, HEPTYLPHYSOSTIGMINE, IN VIEW OF ITS USE IN PATIENTS WITH ALZHEIMER-TYPE DEMENTIA [J].
BRUFANI, M ;
MARTA, M ;
POMPONI, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 157 (01) :115-120
[5]   A LONG-LASTING CHOLINESTERASE INHIBITOR AFFECTING NEURAL AND BEHAVIORAL PROCESSES [J].
BRUFANI, M ;
CASTELLANO, C ;
MARTA, M ;
OLIVERIO, A ;
PAGELLA, PG ;
PAVONE, F ;
POMPONI, M ;
RUGARLI, PL .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 26 (03) :625-629
[6]  
BRUFANI M, 1987, Acta Medica Romana, V25, P202
[7]   THE EFFECT OF HEPTYL-PHYSOSTIGMINE, A NEW CHOLINESTERASE INHIBITOR, ON THE CENTRAL CHOLINERGIC SYSTEM OF THE RAT [J].
DESARNO, P ;
POMPONI, M ;
GIACOBINI, E ;
TANG, XC ;
WILLIAMS, E .
NEUROCHEMICAL RESEARCH, 1989, 14 (10) :971-977
[8]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[9]  
HOLFORD N, 1986, MKMODEL MANUAL EXTEN
[10]  
MARTA M, 1988, LIFE SCI, V43, P1988